Performance of polymyxin B agar-based tests among carbapenem-resistant Enterobacterales

Lett Appl Microbiol. 2021 Jun;72(6):767-773. doi: 10.1111/lam.13467. Epub 2021 Mar 23.

Abstract

Therapeutic options for infections caused by Carbapenem-resistant Enterobacterales (CRE) are restricted and include polymyxins-centred schemes. Evaluation of in vitro susceptibility is difficult and time consuming. Agar-based methodologies are an alternative to broth microdilution (BMD) and we aimed to evaluate the accuracy of those methods among Enterobacterales. A total of 137 non-duplicated CRE were subjected to polymyxin B BMD, agar screening test (Mueller Hinton plates containing 3 µg ml-1 of polymyxin B) and agar dilution (antibiotic serially diluted 0·25-64 µg ml-1 ). CRE of 42·3% were resistant to polymyxin B (MICs range: 0·25->64 µg ml-1 ) and 16·8% presented borderline MICs. Sensitivity, specificity, PPV and NPV were 86·2, 98·7, 98 and 90·7% for screening test and 86·2, 97·5, 96·1 and 90·6% for agar dilution. ME was 0·73 and 1·5% for screening and agar dilution respectively; VME was 5·8% for both techniques. In general, agar-based methods had a good performance. As far as we know, this is the first study to propose an agar screening test using polymyxin B instead of colistin.

Keywords: agar-based tests; alternative susceptibility detection; carbapenem-resistant Enterobacterales; polymyxin B; polymyxin B resistance.

MeSH terms

  • Agar / chemistry
  • Anti-Bacterial Agents / pharmacology*
  • Carbapenem-Resistant Enterobacteriaceae / drug effects*
  • Carbapenem-Resistant Enterobacteriaceae / growth & development*
  • Carbapenems
  • Colistin / pharmacology
  • Humans
  • Microbial Sensitivity Tests
  • Polymyxin B / pharmacology*
  • Polymyxins

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • Polymyxins
  • Agar
  • Polymyxin B
  • Colistin